McKesson Launches Precision Care Companion to Streamline Genomic Testing in Cancer Treatment

McKesson Launches Precision Care Companion to Streamline Genomic Testing in Cancer Treatment

Recognizing the critical role genomic testing and targeted therapies play today in providing high-quality cancer treatment, McKesson has

McKesson Launches Precision Care Companion for Biomarker-Driven Cancer Care

What You Should Know:  – McKesson has unveiled the Precision Care Companion (PCC), a transformative initiative designed to tackle the multifaceted challenges that healthcare practices face in the rapidly evolving landscape of genomic testing and targeted therapies.  – The Precision Care Companion is structured as a consortium of leading industry experts, spearheaded by McKesson. This collaborative model is intentionally designed to foster a dyna…

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

McKesson Launches Collaboration to Boost Precision Oncology Adoption

McKesson has launched the Precision Care Companion (PCC) to help healthcare cancer practices integrate precision medicine into their routine practice. This consortium of industry experts provides targeted education, technology enhancements, operational best practices, and detailed analytics on biomarker testing rates for different cancer diagnoses. “In the rapidly evolving field of biomarker testing, staying current with the latest science and t…